FDA approves Amgen's cheaper copy of arthritis drug Humira

Reuters Health Information: FDA approves Amgen's cheaper copy of arthritis drug Humira

FDA approves Amgen's cheaper copy of arthritis drug Humira

Last Updated: 2016-09-23

By Reuters Staff

WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.

The drug, Amjevita, known also as adalimumab-atto, is made by biotechnology company Amgen Inc and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis and other conditions.

Amjevita is the fourth biosimilar to be approved by the FDA. Last month it approved Novartis AG's biosimilar version of Amgen's arthritis drug, Enbrel (etanercept).

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.